Susan G. Kreissman, MD

AddThis

Print

email this


Professor of Pediatrics
Department / Division:
Pediatrics / Pediatrics-Hematology/Oncology
Address:
DUMC 102382
Durham, NC 27710
Appointment Telephone:
919-684-3401
Office Telephone:
919-684-3401
Fax:
919-681-7950
Training:
  • MD, New York University Mount Sinai School of Medicine, 1985
Residency:
  • Pediatrics, Children's Hospital at Harvard (Massachusetts), 1985-1988
Fellowship:
  • Pediatric Hematology-Oncology, Children's Hospital, Dana Farber Cancer Center (Massachusetts)
Clinical Interests:
Pediatric oncology, new therapeutics for neuroblastoma, apheresis, high-dose chemotherapy, clinical trials in childhood cancer
Research Interests:
The emphasis of Dr Kreissman's clinical research involves the study of childhood neuroblastoma. Neuroblastoma is the most common extracranial solid tumor of childhood and this disease has a diverse clinical phenotype and prognosis. Dr Kreissman has developed, written, and served as national protocol chairman for 2 clinical trials designed to improve outcome for children with the high risk form of this disease through the Children's Oncology Group (COG). Results of this protocol have been published " A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma" and established the new standard of using unpurged PBSC to support autologous transplant in high risk neuroblastoma. Dr. Kreissman also serves as a member of the Neuroblastoma committees for COG and is PI for COG studies at Duke. She is involved in designing and implimenting additional new protocols for the treatment of neuroblastoma.
Representative Publications:
  • Bensimhon, P; Villablanca, JG; Sender, LS; Matthay, KK; Park, JR; Seeger, R; London, WB; Yap, JS; Kreissman, SG. Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group. Pediatric Blood & Cancer. 2010;54:596-602.  Abstract
  • Cairo, MS; Davenport, V; Bessmertny, O; Goldman, SC; Berg, SL; Kreissman, SG; Laver, J; Shen, V; Secola, R; van de Ven, C; Reaman, GH. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. British Journal of Haematology. 2005;128:49-58.  Abstract
  • Kreissman, SG; Rackoff, W; Lee, M; Breitfeld, PP. High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors. Journal of Pediatric Hematology/Oncology. 1997;19:309-312.  Abstract
  • Kreissman, SG. Molecular genetics: toward an understanding of childhood cancer. Seminars in Pediatric Surgery. 1993;2:2-10.  Abstract
  • West, DC; Shamberger, RC; Macklis, RM; Kozakewich, HP; Wayne, AS; Kreissman, SG; Korf, BR; Lavally, B; Grier, HE. Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents. Journal of Clinical Oncology. 1993;11:84-90.  Abstract
  • Kreissman, SG; Gelber, RD; Cohen, HJ; Clavell, LA; Leavitt, P; Sallan, SE. Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia. Cancer. 1992;70:2208-2213.  Abstract